Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Purchases 2,300 Shares

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 2,300 shares of the stock in a transaction dated Friday, October 31st. The shares were acquired at an average cost of $9.26 per share, for a total transaction of $21,298.00. Following the completion of the acquisition, the chief executive officer owned 5,572,902 shares of the company’s stock, valued at approximately $51,605,072.52. This represents a 0.04% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Greenwich LifeSciences Price Performance

Shares of NASDAQ:GLSI opened at $8.43 on Tuesday. The company has a market cap of $114.90 million, a P/E ratio of -6.20 and a beta of 1.61. Greenwich LifeSciences, Inc. has a 1 year low of $8.06 and a 1 year high of $15.47. The stock’s fifty day moving average price is $10.61 and its 200-day moving average price is $10.43.

Greenwich LifeSciences (NASDAQ:GLSI) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.06). On average, sell-side analysts anticipate that Greenwich LifeSciences, Inc. will post -0.8 earnings per share for the current year.

Wall Street Analyst Weigh In

GLSI has been the topic of a number of research analyst reports. Noble Financial initiated coverage on Greenwich LifeSciences in a report on Wednesday, August 20th. They set an “outperform” rating and a $45.00 price target on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Greenwich LifeSciences in a research report on Tuesday, October 14th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $42.00.

Institutional Trading of Greenwich LifeSciences

A number of hedge funds have recently bought and sold shares of the company. Marshall Wace LLP purchased a new stake in Greenwich LifeSciences in the second quarter worth about $509,000. Strs Ohio purchased a new stake in Greenwich LifeSciences in the first quarter worth about $177,000. HighTower Advisors LLC purchased a new stake in Greenwich LifeSciences in the first quarter worth about $147,000. Rhumbline Advisers increased its position in Greenwich LifeSciences by 48.7% in the first quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock worth $92,000 after buying an additional 3,168 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey purchased a new stake in Greenwich LifeSciences in the second quarter worth about $25,000. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.